RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics and its subsidiary Aclipse One Inc (“Aclipse” or “the Company”), an innovative biopharmaceutical company, today announced that the Company has ...

Enrollment currently scheduled to begin in Q1 2026 M107 is the first potential disease-modifying drug for the treatment of gastroparesis M107’s mechanism of action has been shown to shift ...

KING OF PRUSSIA, Pa., November 17, 2025--(BUSINESS WIRE)--Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement ...

Chong Kun Dang said on the 27th that its global partner, Aclipse Therapeutics, signed an agreement with the Mayo Clinic for a phase 2 clinical trial of the gastroparesis treatment candidate "M107 ...

Chong Kun Dang announced on the 27th that its global license partner for the novel diabetes drug lobeglitazone (brand name Duvie), Aclipse Therapeutics, has signed an agreement with the Mayo Clinic in ...

Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDA RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In other news, Windtree Therapeutics' experimental ...